XIAOMI-W
01810
BABA-W
09988
ALI HEALTH
00241
KUAISHOU-W
01024
BIDU-SW
09888
(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Cash flow from operating activities | ||||||||||
Earning before tax | ---- | 35.21%-717.33M | ---- | 18.77%-2.18B | ---- | 18.91%-1.11B | ---- | -68.89%-2.69B | ---- | -126.49%-1.37B |
Profit adjustment | ||||||||||
Investment loss (gain) | ---- | -96.56%10K | ---- | ---- | ---- | --291K | ---- | ---- | ---- | ---- |
Impairment and provisions: | ---- | -71.23%137.25M | ---- | 216.85%1.17B | ---- | 214.50%477M | ---- | 229.49%369.08M | ---- | 757.99%151.67M |
-Other impairments and provisions | ---- | -71.23%137.25M | ---- | 216.85%1.17B | ---- | 214.50%477M | ---- | 229.49%369.08M | ---- | 757.99%151.67M |
Revaluation surplus: | ---- | -17.80%16.03M | ---- | -12.67%25.21M | ---- | -14.65%19.5M | ---- | 135.96%28.87M | ---- | 247.49%22.84M |
-Other fair value changes | ---- | -17.80%16.03M | ---- | -12.67%25.21M | ---- | -14.65%19.5M | ---- | 135.96%28.87M | ---- | 247.49%22.84M |
Asset sale loss (gain): | ---- | -209.92%-23.82M | ---- | -41.39%16.87M | ---- | 787.35%21.67M | ---- | 277.96%28.79M | ---- | 44.34%-3.15M |
-Loss (gain) from sale of subsidiary company | ---- | ---- | ---- | ---6.02M | ---- | ---- | ---- | ---- | ---- | --123K |
-Loss (gain) on sale of property, machinery and equipment | ---- | -209.92%-23.82M | ---- | -20.12%23M | ---- | 761.54%21.67M | ---- | 595.15%28.79M | ---- | -23,300.00%-3.28M |
-Loss (gain) from selling other assets | ---- | ---- | ---- | ---100K | ---- | ---- | ---- | ---- | ---- | ---- |
Depreciation and amortization: | ---- | 3.51%528.45M | ---- | -18.74%940.48M | ---- | -11.71%510.52M | ---- | 35.28%1.16B | ---- | 56.45%578.24M |
-Depreciation | ---- | 3.51%528.45M | ---- | -18.74%940.48M | ---- | -11.71%510.52M | ---- | 35.28%1.16B | ---- | 56.45%578.24M |
Exchange Loss (gain) | ---- | -67.15%49.74M | ---- | -82.90%57.21M | ---- | -38.94%151.42M | ---- | 984.75%334.63M | ---- | 1,182.78%247.98M |
Special items | ---- | 165.62%123.8M | ---- | -54.15%199.78M | ---- | -78.85%46.61M | ---- | -8.29%435.76M | ---- | -2.29%220.42M |
Operating profit before the change of operating capital | ---- | -4.84%114.11M | ---- | 167.50%225.35M | ---- | 181.41%119.91M | ---- | -17.85%-333.84M | ---- | -333.15%-147.3M |
Change of operating capital | ||||||||||
Accounts receivable (increase)decrease | ---- | -30,022.94%-294.74M | ---- | -54.03%362.24M | ---- | -99.76%985K | ---- | 182.96%788.01M | ---- | 140.06%410.38M |
Accounts payable increase (decrease) | ---- | 194.15%160.04M | ---- | -46.61%-511.47M | ---- | 66.79%-169.97M | ---- | -169.16%-348.87M | ---- | -326.58%-511.8M |
prepayments (increase)decrease | ---- | -5.59%-109.25M | ---- | -263.08%-216.3M | ---- | -824.04%-103.46M | ---- | 329.49%132.64M | ---- | -79.77%14.29M |
Cash from business operations | ---- | 14.88%-129.84M | ---- | -158.92%-140.19M | ---- | 34.93%-152.54M | ---- | 134.10%237.94M | ---- | 69.23%-234.43M |
Other taxs | ---- | -161.35%-4.78M | ---- | 261.92%8.52M | ---- | 151.49%7.78M | ---- | -125.40%-5.26M | ---- | -467.40%-15.12M |
Special items of business | 131.32%58.2M | 42.10%-35.55M | -18.41%-321.34M | 14.42%-37.4M | -2.38%-185.79M | -86.86%-61.4M | -3,109.78%-271.39M | -37.46%-43.7M | -603.95%-181.47M | -992.82%-32.86M |
Net cash from operations | 131.32%58.2M | 17.46%-170.17M | -18.41%-321.34M | -189.47%-169.07M | -2.38%-185.79M | 27.00%-206.16M | 56.65%-271.39M | 126.66%188.97M | 75.70%-181.47M | 62.88%-282.4M |
Cash flow from investment activities | ||||||||||
Sale of fixed assets | ---- | -99.93%8K | ---- | -64.46%12.31M | ---- | 134.46%12.23M | ---- | 316.34%34.64M | ---- | 5,630.77%5.22M |
Purchase of fixed assets | ---- | -1,296.86%-1.87B | ---- | -38.07%-1.96B | ---- | 87.42%-133.61M | ---- | -96.14%-1.42B | ---- | -146.54%-1.06B |
Purchase of intangible assets | ---- | ---706K | ---- | 68.15%-5.98M | ---- | ---- | ---- | -55.08%-18.77M | ---- | -154.72%-11.18M |
Sale of subsidiaries | ---- | ---- | ---- | 253.36%3.95M | ---- | ---- | ---- | ---2.58M | ---- | ---2.58M |
Recovery of cash from investments | ---- | ---- | ---- | -54.66%1.83B | ---- | -43.31%1.26B | ---- | 45.25%4.04B | ---- | 1.33%2.22B |
Cash on investment | ---- | 99.51%-2.77M | ---- | 79.71%-562.22M | ---- | 76.83%-559.95M | ---- | -11.64%-2.77B | ---- | -17.92%-2.42B |
Other items in the investment business | -407.79%-2.28B | --45.92M | -465.69%-1.17B | -95.61%4.37M | 179.41%741.58M | ---- | --319.67M | 2,959.02%99.57M | -30,271.76%-933.82M | 1,775.00%11.25M |
Net cash from investment operations | -407.79%-2.28B | -416.37%-1.82B | -465.69%-1.17B | -1,948.34%-673.19M | 179.41%741.58M | 145.84%576.49M | 160.92%319.67M | 92.21%-32.87M | -378.62%-933.82M | -326.95%-1.26B |
Net cash before financing | -500.20%-2.22B | -638.44%-1.99B | -3,186.70%-1.49B | -639.53%-842.26M | 149.83%555.79M | 124.05%370.33M | 104.20%48.28M | 113.81%156.11M | -18.40%-1.12B | -45.92%-1.54B |
Cash flow from financing activities | ||||||||||
New borrowing | ---- | 352.46%2.46B | ---- | 75.02%2.16B | ---- | 10.72%544M | ---- | -54.74%1.24B | ---- | -36.84%491.33M |
Refund | ---- | -22.24%-751.7M | ---- | 19.99%-1.7B | ---- | 10.07%-614.91M | ---- | -273.17%-2.13B | ---- | -272.42%-683.76M |
Issuing shares | ---- | 48.29%3.17M | ---- | -78.39%3.85M | ---- | -79.68%2.14M | ---- | -65.04%17.8M | ---- | 49.43%10.51M |
Absorb investment income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --2.14M | ---- | --2.14M |
Issuance expenses and redemption of securities expenses | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---233.72M | ---- | ---35.02M |
Other items of the financing business | 205.06%1.45B | -5.16%-52.58M | 969.38%1.11B | -1,441.14%-677.81M | -300.20%-1.38B | ---50M | 35,114.81%103.99M | ---43.98M | ---345.49M | ---- |
Net cash from financing operations | 205.06%1.45B | 1,477.46%1.64B | 969.38%1.11B | 80.22%-227.85M | -300.20%-1.38B | 44.70%-118.77M | 6.54%103.99M | -152.07%-1.15B | -130.64%-345.49M | -135.72%-214.8M |
Effect of rate | -130.18%-7.48M | -192.87%-35.11M | -3.26%-20.46M | -64.64%25.86M | -88.23%24.78M | -49.54%37.81M | 5.70%-19.82M | 246.14%73.14M | 1,467.49%210.51M | 567.93%74.92M |
Net Cash | 6.68%-771.61M | -242.30%-357.97M | -348.40%-378.26M | -7.44%-1.07B | 43.39%-826.88M | 114.34%251.56M | 114.46%152.28M | -192.06%-996.04M | -887.54%-1.46B | -286.47%-1.75B |
Begining period cash | -29.55%2.49B | -29.55%2.49B | -29.55%2.49B | -20.71%3.53B | -20.71%3.53B | -20.71%3.53B | -20.71%3.53B | 30.13%4.46B | 30.13%4.46B | 30.13%4.46B |
Cash at the end | -37.39%1.71B | -45.16%2.1B | -42.97%2.09B | -29.55%2.49B | -14.81%2.73B | 37.68%3.82B | 8.39%3.67B | -20.71%3.53B | -10.80%3.21B | -6.02%2.78B |
Cash balance analysis | ||||||||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | UAS | UAS | UAS | UAS | UAS | UAS | UAS | UAS | UAS | UAS |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
Auditor | -- | -- | -- | Ernst & Young | -- | -- | -- | Ernst & Young | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.